Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov;83(9):1192–1201. doi: 10.1054/bjoc.2000.1415

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?

W Walter 1, K Lingnau 2, E Schmitt 2, M Loos 1, M J Maeurer 1
PMCID: PMC2363595  PMID: 11027433

Abstract

Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the β-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1β-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) α-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-γ) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Mαβ1 and Mαβ2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-Ad- and H2-Ed-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-γ-treatment; and lack of constitutive and IFN-γ-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models. © 2000 Cancer Research Campaign

Keywords: MHC, gene regulation, transcription factors, antigen processing

Full Text

The Full Text of this article is available as a PDF (228.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agarwal S., Rao A. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity. 1998 Dec;9(6):765–775. doi: 10.1016/s1074-7613(00)80642-1. [DOI] [PubMed] [Google Scholar]
  2. Armstrong T. D., Clements V. K., Martin B. K., Ting J. P., Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886–6891. doi: 10.1073/pnas.94.13.6886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bakke O., Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell. 1990 Nov 16;63(4):707–716. doi: 10.1016/0092-8674(90)90137-4. [DOI] [PubMed] [Google Scholar]
  4. Becker-André M., Hahlbrock K. Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res. 1989 Nov 25;17(22):9437–9446. doi: 10.1093/nar/17.22.9437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bouaboula M., Legoux P., Pességué B., Delpech B., Dumont X., Piechaczyk M., Casellas P., Shire D. Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control. J Biol Chem. 1992 Oct 25;267(30):21830–21838. [PubMed] [Google Scholar]
  6. Chang C. H., Guerder S., Hong S. C., van Ewijk W., Flavell R. A. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity. 1996 Feb;4(2):167–178. doi: 10.1016/s1074-7613(00)80681-0. [DOI] [PubMed] [Google Scholar]
  7. Cho S. G., Attaya M., Monaco J. J. New class II-like genes in the murine MHC. Nature. 1991 Oct 10;353(6344):573–576. doi: 10.1038/353573a0. [DOI] [PubMed] [Google Scholar]
  8. Cresswell P. Invariant chain structure and MHC class II function. Cell. 1996 Feb 23;84(4):505–507. doi: 10.1016/s0092-8674(00)81025-9. [DOI] [PubMed] [Google Scholar]
  9. Cresswell P. Proteases, processing, and thymic selection. Science. 1998 Apr 17;280(5362):394–395. doi: 10.1126/science.280.5362.394. [DOI] [PubMed] [Google Scholar]
  10. Denzin L. K., Hammond C., Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med. 1996 Dec 1;184(6):2153–2165. doi: 10.1084/jem.184.6.2153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Denzin L. K., Robbins N. F., Carboy-Newcomb C., Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity. 1994 Oct;1(7):595–606. doi: 10.1016/1074-7613(94)90049-3. [DOI] [PubMed] [Google Scholar]
  12. Fremont D. H., Crawford F., Marrack P., Hendrickson W. A., Kappler J. Crystal structure of mouse H2-M. Immunity. 1998 Sep;9(3):385–393. doi: 10.1016/s1074-7613(00)80621-4. [DOI] [PubMed] [Google Scholar]
  13. Haberhausen G., Pinsl J., Kuhn C. C., Markert-Hahn C. Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assays. J Clin Microbiol. 1998 Mar;36(3):628–633. doi: 10.1128/jcm.36.3.628-633.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hardison R. Hemoglobins from bacteria to man: evolution of different patterns of gene expression. J Exp Biol. 1998 Apr;201(Pt 8):1099–1117. doi: 10.1242/jeb.201.8.1099. [DOI] [PubMed] [Google Scholar]
  15. Hsieh C. L. Stability of patch methylation and its impact in regions of transcriptional initiation and elongation. Mol Cell Biol. 1997 Oct;17(10):5897–5904. doi: 10.1128/mcb.17.10.5897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kelly A. P., Monaco J. J., Cho S. G., Trowsdale J. A new human HLA class II-related locus, DM. Nature. 1991 Oct 10;353(6344):571–573. doi: 10.1038/353571a0. [DOI] [PubMed] [Google Scholar]
  17. Kerkmann-Tucek A., Banat G. A., Cochlovius B., Zöller M. Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination. Int J Cancer. 1998 Jul 3;77(1):114–122. doi: 10.1002/(sici)1097-0215(19980703)77:1<114::aid-ijc18>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  18. Kirberg J., Baron A., Jakob S., Rolink A., Karjalainen K., von Boehmer H. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med. 1994 Jul 1;180(1):25–34. doi: 10.1084/jem.180.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kleijmeer M. J., Morkowski S., Griffith J. M., Rudensky A. Y., Geuze H. J. Major histocompatibility complex class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments. J Cell Biol. 1997 Nov 3;139(3):639–649. doi: 10.1083/jcb.139.3.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lingnau K., Hoehn P., Kerdine S., Koelsch S., Neudoerfl C., Palm N., Ruede E., Schmitt E. IL-4 in combination with TGF-beta favors an alternative pathway of Th1 development independent of IL-12. J Immunol. 1998 Nov 1;161(9):4709–4718. [PubMed] [Google Scholar]
  21. Mach B., Steimle V., Martinez-Soria E., Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol. 1996;14:301–331. doi: 10.1146/annurev.immunol.14.1.301. [DOI] [PubMed] [Google Scholar]
  22. Miyazaki T., Wolf P., Tourne S., Waltzinger C., Dierich A., Barois N., Ploegh H., Benoist C., Mathis D. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell. 1996 Feb 23;84(4):531–541. doi: 10.1016/s0092-8674(00)81029-6. [DOI] [PubMed] [Google Scholar]
  23. Mongini C., Sánchez Lockhart M., Waldner C. I., Alvarez E. M., Gravisaco M. J., Roig M. I., Hajos S. E. Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection. Br J Cancer. 1996 Jul;74(2):258–263. doi: 10.1038/bjc.1996.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Muhlethaler-Mottet A., Otten L. A., Steimle V., Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997 May 15;16(10):2851–2860. doi: 10.1093/emboj/16.10.2851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Murphy K. M., Heimberger A. B., Loh D. Y. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science. 1990 Dec 21;250(4988):1720–1723. doi: 10.1126/science.2125367. [DOI] [PubMed] [Google Scholar]
  26. Ossendorp F., Mengedé E., Camps M., Filius R., Melief C. J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998 Mar 2;187(5):693–702. doi: 10.1084/jem.187.5.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pardoll D. M., Topalian S. L. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998 Oct;10(5):588–594. doi: 10.1016/s0952-7915(98)80228-8. [DOI] [PubMed] [Google Scholar]
  28. Péléraux A., Karlsson L., Chambers J., Peterson P. A. Genomic organization of a mouse MHC class II region including the H2-M and Lmp2 loci. Immunogenetics. 1996;43(4):204–214. doi: 10.1007/BF00587301. [DOI] [PubMed] [Google Scholar]
  29. Riberdy J. M., Newcomb J. R., Surman M. J., Barbosa J. A., Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature. 1992 Dec 3;360(6403):474–477. doi: 10.1038/360474a0. [DOI] [PubMed] [Google Scholar]
  30. Sanderson F., Thomas C., Neefjes J., Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity. 1996 Jan;4(1):87–96. doi: 10.1016/s1074-7613(00)80301-5. [DOI] [PubMed] [Google Scholar]
  31. Sartoris S., Valle M. T., Barbaro A. L., Tosi G., Cestari T., D'Agostino A., Megiovanni A. M., Manca F., Accolla R. S. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J Immunol. 1998 Jul 15;161(2):814–820. [PubMed] [Google Scholar]
  32. Scholl T., Mahanta S. K., Strominger J. L. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6330–6334. doi: 10.1073/pnas.94.12.6330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sette A., Southwood S., Miller J., Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med. 1995 Feb 1;181(2):677–683. doi: 10.1084/jem.181.2.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Urban R. G., Chicz R. M., Strominger J. L. Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J Exp Med. 1994 Aug 1;180(2):751–755. doi: 10.1084/jem.180.2.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Walter W., Loos M., Maeurer M. J. H2-M polymorphism in mice susceptible to collagen-induced arthritis involves the peptide binding groove. Immunogenetics. 1996;44(1):19–26. [PubMed] [Google Scholar]
  36. Westerheide S. D., Louis-Plence P., Ping D., He X. F., Boss J. M. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region. J Immunol. 1997 May 15;158(10):4812–4821. [PubMed] [Google Scholar]
  37. Wolf P. R., Ploegh H. L. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol. 1995;11:267–306. doi: 10.1146/annurev.cb.11.110195.001411. [DOI] [PubMed] [Google Scholar]
  38. Wolf P. R., Tourne S., Miyazaki T., Benoist C., Mathis D., Ploegh H. L. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol. 1998 Sep;28(9):2605–2618. doi: 10.1002/(SICI)1521-4141(199809)28:09<2605::AID-IMMU2605>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  39. van Ham S. M., Grüneberg U., Malcherek G., Bröker I., Melms A., Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med. 1996 Nov 1;184(5):2019–2024. doi: 10.1084/jem.184.5.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES